Genzyme receives positive CHMP opinion for Lemtrada™
Posted: Fri Jun 28, 2013 5:34 am
Genzyme receives positive CHMP opinion for Lemtrada™ (alemtuzumab) in Europe
CHMP also Recommends NAS Designation for Aubagio® (teriflunomide) Following Positive Opinion on Approval in March 2013
Genzyme announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Lemtrada™ (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features......
Read More - http://www.ms-uk.org/index.cfm/lemtrada
CHMP also Recommends NAS Designation for Aubagio® (teriflunomide) Following Positive Opinion on Approval in March 2013
Genzyme announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Lemtrada™ (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features......
Read More - http://www.ms-uk.org/index.cfm/lemtrada